# Pfizer’s RSV vaccine shows benefit in immuno-compromised adults in study
Published: 2024-08-13
Category: Headlines
Category URL: https://entrepreneurtribune.com/category/headlines/
Meta Title: Pfizer's Abrysvo RSV Vaccine Generates Strong Immune
Meta Description: Pfizer's Abrysvo RSV vaccine shows promise in generating neutralizing antibodies against RSV-A and RSV-B in adults with compromised immunity. Learn more about the study's results.
URL: https://entrepreneurtribune.com/pfizers-rsv-vaccine-shows-benefit-in-immuno-compromised-adults-in-study/

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qsqu1j002vwirgtlcwq54p/images/2024-08-13t000626z3lynxmpek7b0a7rtroptp3pfizer-europe-1737049944724-compressed.webp)

(Reuters) – [Pfizer](https://entrepreneurtribune.com/pfizer-wins-bid-to-invalidate-gsks-patents-over-rsv-vaccine/) said on Monday its respiratory syncytial virus (RSV) [vaccine](https://entrepreneurtribune.com/gsk-sk-bioscience-to-test-covid-19-vaccine-against-astrazeneca-shot/) Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system.

A single 120 microgram dose of the vaccine generated strong neutralizing antibodies against both subtypes of RSV, called RSV-A and RSV-B, across all groups in the [study,](https://entrepreneurtribune.com/tonixs-long-covid-drug-fails-to-meet-mid-stage-trial-goal/) Pfizer said.

Abrysvo was well-tolerated in the study and showed a safety profile consistent with findings from other studies of the vaccine, it added.

The drugmaker plans to submit the data to regulatory agencies for review.

The [study](https://entrepreneurtribune.com/tonixs-long-covid-drug-fails-to-meet-mid-stage-trial-goal/) tested two doses of Abrysvo in 203 adults across four groups – those with a type of lung cancer, end-stage kidney disease, autoimmune inflammatory disorder, and solid organ transplant recipients – all of whom have compromised immunity and are at risk of developing severe RSV-associated disease.

Pfizer’s [vaccine](https://entrepreneurtribune.com/gsk-sk-bioscience-to-test-covid-19-vaccine-against-astrazeneca-shot/) is currently approved for people aged 60 and older and for use in women during the middle of the third trimester of pregnancy to protect their babies.

RSV typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults, leading to 177,000 hospitalizations and 14,000 deaths in the United States annually.

(Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---